CA-NEXON-AMERICA-INC
14.5.2020 05:02:10 CEST | Business Wire | Press release
The highly-anticipated free to play kart racing game, KartRider: Drift , will hold its second Closed Beta starting June 3, 2020 via the Nexon Launcher, Steam, and Xbox One, including Xbox One X delivering cross-platform play. Players can register here for a chance to join the second Closed Beta starting today!
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200513005906/en/
Players invited to the second Closed Beta will receive an acceptance email, and they can pre-download the game starting on June 1, 2020 at 7 p.m. PDT. Players who participated in the first Closed Beta will automatically be included.
During the Closed Beta period, players will be introduced to a new character — Diz, as well as new skins for existing characters, plus additional karts and tracks. The Closed Beta will also showcase new functions such as Racing Pass and a new Racing School single-player mode, where new and experienced players can improve their racing skills.
Customization will be a huge part of this Closed Beta with the preview of the new wraps, which allows racers to paint their karts and create unique designs for maximum personalization. Participants will also have access to kart upgrades including choice of license plate and can decorate their karts with a lineup of new accessory balloons and character emotes.
Players will also see a revamped User Interface with a new HUD and contextual rear view mirror. The matchmaking experience has also been improved as players will be queued based on their performance in the tutorial. Driving physics of the game have also been improved since the first Closed Beta for a better racing experience.
To reward players who log in during the Closed Beta, special login rewards including a Turbo Tortoise Kart, Bunny Buggy Kart, Simian Scrapper Kart, and Deuce Coupe Kart will be unlocked. All Beta participants will also receive a White Cloud Balloon item at official launch.
Players who sign up for Closed Beta 2 at www.kartriderdrift.net will be in for a treat as KartRider: Drift has partnered with HyperX, ViewSonic and DXRacer, for an opportunity to win exclusive prizes.
KartRider: Drift’s Closed Beta will be available worldwide on the Nexon Launcher, Steam, Xbox One, including Xbox One X, with the exception of Japan, and China on console. To see a full list of available regions, please follow this link .
For more information on KartRider: Drift , visit www.kartriderdrift.net or follow @KartRiderDrift on Twitter for the latest updates and information on contests and giveaways.
Social Media: Facebook / Twitter / Instagram / Discord / Official Site
Press Assets:
About KartRider: Drift http://kartrider.nexon.net/
Launched in 2004, KartRider is a massively popular multiplayer racing franchise that boasts more than 300 million PC players. Making its debut to western audiences, KartRider: Drift takes inspiration from earlier iterations of the game, delivering competitive drift-fueled racing action, featuring different game modes, and deep character + kart customization. Available completely for free on PC Steam, Xbox One, including Xbox One X, and Nexon Launcher (PC), KartRider: Drift offers cross-platform capabilities to challenge friends regardless of the platform they choose or where they are in the world.
About Nexon America Inc. http://www.nexon.net/corporate/about-nexon/
Founded in 2005, Nexon America Inc. delivers outstanding free-to-play online game expertise and live game support, taking the strengths of NEXON Co., Ltd. (“Nexon”) and applying them for uniquely western audiences. Nexon America has consistently sustained iconic franchises such as MapleStory and Mabinogi for more than a decade, which have gone on to break records and captivate players. With new projects on the horizon, Nexon America maintains the pioneering and innovative spirit of its parent company, employing its player-first approach, while designing the best possible gameplay experiences for the western market.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200513005906/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom